Repros Therapeutics Gains 4%

Shares of Repros Therapeutics were up over 4% Monday morning after the company said the U.S. Food and Drug Administration granted an “end of phase 2” meeting to discuss the phase 3 requirements to study Proellex to treat uterine fibroids.

The meeting is scheduled to occur before the end of April. In the phase 2 study, leading up to the meeting request, Proellex successfully induced amenorrhea (cessation of menses) in greater than 90% of subjects after two 18-week treatment cycles. The drug was generally well tolerated.